This acquisition will help generate data from over four million members of MyHealthTeams’ opted-in patient universe.

The regulator is requiring labeling that warns of Guillan-Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised about $500 million privately, has a drug in Phase 2 testing.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to watch in 2025.

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its current workforce.

Both companies have produced AI-powered technology that improves data collection and analysis.

China’s National Medical Products Administration has granted expanded approval to MSD’s GARDASIL for use in males aged nine to 26 years.

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Actuate Therapeutics has gained OMPD from the EMA for elraglusib aimed at treating pancreatic ductal adenocarcinoma (PDAC).

Deloitte’s US life sciences sector leader discusses the trends he believes will have the most impact in 2025.

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.

The latest news for pharma industry insiders.

Sickle cell patient advocacy groups in the US are calling for greater education on the disease and increasing awareness of blood therapy.

GSK has gained US FDA breakthrough therapy designation for GSK’227 to treat adults with relapsed or refractory osteosarcoma.

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).

The addition of Peregrine builds on Klick’s market access execution capabilities.

Fast Track designation was based on results from a Phase II study, which demonstrated that VGT-309 was safe, well-tolerated, and enhanced tumor visualization in lung cancer patients.